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Abstract Translin is a DNA binding protein which specifically 
binds to consensus sequences at breakpoint junctions of 
chromosomal translocations in many cases of lymphoid malig-
nancies. To investigate its functional significance at such 
recombination hotspots, we examined whether Translin interacts 
with other proteins using a yeast two-hybrid system and 
identified an associated 33 kd protein partner, TRAX, with 
extensive amino acid homology. The TRAX protein was 
established to contain bipartite nuclear targeting sequences in 
its N-terminal region, suggesting a possible role in the selective 
nuclear transport of Translin protein lacking any nuclear 
targeting motifs. 
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1. Introduction 
Aberrant chromosomal rearrangements in human lymphoid 
neoplasms have been found to occur frequently at chromoso-
mal loci where T-cell receptor (TCR) or immunoglobulin (Ig) 
genes are located, and appear to play a significant role in 
tumor etiology by dysregulating expression of cellular proto-
oncogenes [1]. It has been suggested that the V-D-J recombi-
nase is involved in such interchromosomal rearrangements by 
recognizing heptamer-nonamer signal sequences [2-4]. In pre-
vious studies, however, we found consensus sequences not 
resembling the signal sequences for Ig/TCR recombinase at 
breakpoint junctions of chromosomal translocations in 
many cases of lymphoid neoplasms [5-7]. Subsequently, a 
novel protein, Translin, exhibiting general binding activity 
to the above consensus sequences was identified and its 
cDNA was cloned [8]. Biochemical and electron microscopic 
studies revealed that Translin polypeptides are held together 
by disulfide bonds [8] and the subunit of native Translin is a 
ring-shaped structure which is responsible for its binding to 
target sequences situated only at single-strand DNA ends 
(manuscript in preparation). In the present investigation, to 
provide further insight into Translin function, we used a yeast 
two-hybrid system [9] to examine whether it might be a mem-
ber of a multicomponent complex and cloned a cDNA encod-
ing TRAX (i.e. Translin-associated factor X) showing exten-
sive homology with Translin. 
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2. Materials and methods 
2.1. Yeast two-hybrid cloning 
DNA encoding the Translin domain was cloned into the yeast 
GAL4 DNA-binding domain vector, pGBT9 (Clontech). The result-
ing plasmid, GAL4bd-Tra (ORF), was used as bait to screen a human 
spleen cDNA library in two-hybrid interaction analysis which was 
performed following the Matchmaker Two-Hybrid System Protocol 
(Clontech). Positive yeast clones were screened by activation of his 
and lacZ reporter genes. After transformation of yeast DNA into E. 
coli, pGADIO plasmids (Clontech) containing cDNA clones were 
identified by restriction mapping and further characterized by DNA 
sequencing. 
2.2. DNA sequencing 
The cDNA inserts of the isolated clones were subcloned into pBlue-
script SK (Stratagene) and DNA sequencing was performed by the 
dideoxy chain termination method, using a Taq dye primer cycle 
sequencing kit and an ABI 373A DNA sequencer (Applied Biosys-
tem). The final sequence was confirmed from analyses of both strands. 
2.3. In vitro interaction assays 
GST fusion protein containing the Translin domain was expressed 
using pGEX vectors (Pharmacia) and tested for interaction with 35S-
labeled TRAX fusion protein (41 kDa) and ß-galactosidase fusion 
protein (118 kDa) prepared using an in vitro transcription and trans-
lation system with pCITE-4a(+) (Amersham). For each in vitro bind-
ing assay, aliquots of glutathione-Sepharose beads (Pharmacia) carry-
ing the same amounts of GST or GST/Translin fusion proteins were 
incubated with 35S-labeled TRAX and ß-galactosidase fusion protein 
in low-stringency NP-40 buffer (20 mM HEPES [pH 7.6], 100 mM 
NaCl, 0.1% NP-40, 1 mM EDTA) at 4°C for 1 h. After washing 
several times with the same buffer, proteins on the beads were sub-
jected to 10% SDS-polyacrylamide gel electrophoresis and the 
amounts of radioactivity were measured with a Fujix BAS 2000 
Bio-imaging Analyzer. 
2.4. Amplification of cDNA ends 
5'-Amplification of cDNA ends was carried out using a 5'-RACE 
system (Gibco-BRL). First-strand cDNA was synthesized from 
poly(A)+ RNA of NALL-1 cells (non-T, non-B-ALL) using Moloney 
murine leukemia virus reverse transcriptase (M-MLVRT) and an F2-
specific primer, 5'-GAGACAGCTTCCACATATTC-3' (primer F2-
Rl, complementary to nt 536-555). An anchor sequence was then 
added to the 3' end of the cDNA using terminal deoxynucleotidyl 
transferase (TdT). A nested PCR amplification was performed using 
a primer complementary to the anchor and specific primers, 5'-CAA-
CAGTTATATCCCGACTAAG-3' (primer F2-R2, complementary to 
nt 335-356) and 5'-TGAGACGAGCGGAGACTGAA-3' (primer 
F2-R3, complementary to nt 124-143). The resulting PCR products 
(200 bp) were cloned into pBluescript II and four clones were selected 
for further sequencing. 
3. Results and discussion 
3.1. Molecular cloning of TRAX 
We examined whether Translin might be a member of a 
multicomponent complex using a yeast two-hybrid system. 
DNA encoding the full-length Translin was cloned into the 
yeast GAL4 DNA-binding domain vector and used as bait to 
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AGGAGGGTTCAGGAAAAGGAAGCATGACAA 
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GGCCTTTAAATCATTTCAGCAGGAACTTGA 
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TAAAAGGACAATTTTTCTCCTCCATAGGAT 
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OU^CÄAAAGATATTCCAGGTAGCCCAAGA 
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TCTGGAAGCTGTCTCTTTTCAACACTTCAT 
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CTGTGACGACATGAGCAACAAAGAAGGATC 
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GGATGTTAATTCATCTTCACCCGTGATGTT 
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GAAFTCTTAGTCGGGATATAACTGTTGAAAG 
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GACTGAATCAGAAATTAAATTGGATGGTGT 
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TCGAGCCATTACTACAGGACTACAGGAATA 
R A I T T G L Q E Y 
AATTAATAAACAATTGATATTTACGACTGA 
I N K Q L I F T T E 
TTGGAGACTGAGAGTCACACCTGTCGATTA 
W R L R V T P V D Y 
GAATGGGGACATTGATACCCCCTTTGAAGT 
N G D I D T P F E V 
CGAGGTTTCTAAGAAGCTGTATACCTTGAA 
E V S K K L Y T L K 
TCCAAAACATATG1TGGCAGATGTGTTTTC 
P K H M L A D V F S 
TTACTAATTCTTTTGAGAACTCCTAAGAGA 
TTTCCCACATAACCAAAGAAGAGAÄGGGAA 
F P H N Q R R E G K 
TGCAAGGCATGACAAATATGAGAGACTTGT 
A R H D K Y E R L V 
TACAAGTGCTCCTGATATGGAAGATATÄTT 
T S [ Ä ] P D M E D I [ Γ ] 
GCTATCAGGGGAAGATATGCATCAGTTCCA 
[ L ] S G E D M H Q F H 
CAAAACACGATCATOAATTAGTÄTGGATGA 
K T R S L I S M D E 
CTCTGATGCACAGGATAAGCAGTTTGGTAC 
S D A Q D K Q F G T 
ATTGATGCGGATGTGTATTAACAGTGTGGG 
L M R M C I N S V G 
GTTTTCATTCATTGGCAACACTGGACCTTA 
F S F I G N T G P Y 
TTATGCCTTGAAAGTCAGAGGGTCAGAAAT 
Y A L K V R G S E I 
GGGCATTTCTTAGAATCTAACGTTACTCAG 
G I Ξ * 
TTAACTTTATTGTGGCTTTTACATAGAAAC ATATTCAGTTGTACTTGTTTTAAATTGTAT 
360 
450 
720 
810 
900 
990 
1080 
1170 
1198 
Fig. 1. The nucleotide sequence of the TRAX cDNA and its deduced amino acid sequence. The isolated clone (F2; nt 100-1198) and its 5'-
RACE product (nt 1-143, 9-143, 14-143, 17-143) were combined to construct the composite cDNA. The nucleotide sequence and the deduced 
290 amino acids of the encoded protein are shown. The stop codon is indicated by an asterisk. The periodic repetition of hydrophobic amino 
acids is shown in the open box. The horizontal arrows indicate the sequences targeted by the specific primers (F2-R1, F2-R2, F2-R3) used for 
the 5'-RACE system. The 5' ends of the F2 clone and the four 5'-RACE products are indicated by the vertical arrows. 
screen a human spleen cDNA library in two-hybrid interac-
tion analyses. From screening 6.2 X 106 individual colonies for 
activation of the his reporter gene, 31 clones were obtained. 
Of these 31 clones, six were selected by activation of lacZ 
reporter genes, but five turned out to be non-specific. We 
finally selected the one clone F2 whose product gave specific 
activation with the Translin bait. Nucleotide sequence analysis 
of this clone revealed an open reading frame (ORF) encoding 
a protein of 290 amino acids with a predicted molecular 
weight of 33 kDa (GenBank accession number X95073) 
(Fig. 1). Since there were no stop codons upstream of the 
predicted start methionine, we used RACE PCR to extend 
the insert cDNA in the 5' direction. Analysis of four resultant 
clones resulted in the identification of almost identical addi-
tional 83, 86, 91 and 99 nt sequences preceding the 5' end of 
the original clone. We assumed that the ATG codon at posi-
tions 161-163 of the most extended cDNA was the transla-
tional initiation codon and named the encoded protein TRAX 
(i.e. Translin-associated factor X). The TRAX amino acid 
sequence contains six potential protein kinase C phosphoryla-
tion sites (amino acids 2-Λ, 67-69, 177-179, 240-242, 245-
247, 277-279), eight CK2 phosphorylation sites (amino acids 
Table 1 
Interactions of TRAX and Translin fusion proteins determined by 
activation of the lacZ reporter gene 
DNA-binding hybrid 
A: GAL4bd 
B: GAL4bd-Tra (ORF) 
C: GAL4bd-lamin 
D: GAL4bd-p53 
GAL4bd-Tra (ORF) 
Activation hybrid 
GAL4ad-TRAX 
GAL4ad-TRAX 
GAL4ad-TRAX 
GAL4ad-TRAX 
GAL4ad 
Colony color 
(lacZ activity) 
White 
Blue 
White 
White 
White 
Yeast strains HF7c and SFY526 were cotransformed with the GAL4 
DNA-binding domain vector pGBT9 encoding the full-length Trans-
lin, GAL4bd-Tra (ORF), human lamin C (amino acids 66-230), 
GAL4bd-lamin, and murine p53 (amino acids 72-390), GAL4bd-
p53, and the GAL4 transcription activation domain vector pGADIO 
encoding the full-length TRAX, GAL4ad-TRAX. Each transforma-
tion mixture was plated on plates lacking tryptophan and leucine, 
incubated at 30°C for 3 days, and then transferred to nitrocellulose 
filters for determination of ß-galactosidase activity. 
Fig. 2. Interaction of Translin and TRAX fusion proteins deter-
mined by his reporter gene activation. The yeast strain HF7c was 
cotransformed with the GAL4 DNA-binding domain vector pGBT9 
encoding the domains of various proteins. A: GAL4bd, B: 
GAL4bd-Tra (ORF), C: GAL4bd-lamin, D: GAL4bd-p53, and the 
GAL4 transcription activation domain vector, pGADIO, encoding 
the full-length TRAX, GAL4ad-TRAX. Transformants were 
streaked onto plates lacking tryptophan and leucine, and incubated 
at 30°C for 3 days. Three individual colonies appearing on the 
plates were then streaked onto a plate lacking tryptophan, leucine 
and histidine, and incubated at 30°C for 2 days. 
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2-5, 79-82, 88-91, 109-112, 144-147, 155-158, 183-186, 213-
216) and one ./V-glycosylation site (amino acids 30-33). 
3.2. TRAX specifically interacts with Translin 
To confirm that TRAX interacts specifically with Translin, 
DNA encoding the full-length TRAX was cloned into the 
yeast GAL4 transcription activation domain vector and the 
resulting plasmid, GAL4ad-TRAX was cotransformed with a 
GAL4 binding domain vector encoding the domains of var-
ious proteins including Translin. Interactions were determined 
in terms of the ability to activate a lacZ reporter construct 
(Table 1), as well as the his reporter construct, and to confer 
growth in the absence of histidine (Fig. 2). The GAL4ad-
TRAX fusion protein interacted with Translin, GAL4bd-Tra 
(ORF), but not with human lamin C, GAL4bd-lamin and 
murine p53, GAL4bd-p53. 
To examine further the specificity of the interaction between 
TRAX and Translin observed in the two-hybrid system, the 
GST-Translin fusion protein, GST-Tra (ORF), was tested for 
interaction with 35S-labeled TRAX and ß-galactosidase pre-
pared by in vitro transcription and translation. As observed in 
the two-hybrid system, the GST-Tra (ORF) specifically asso-
ciated with TRAX, but not ß-galactosidase (Fig. 3). 
3.3. Comparison of the deduced amino acid sequence of TRAX 
with that of Translin 
GenBank data base searches using FASTA programs re-
vealed a 28% identity between TRAX and Translin (Fig. 4). 
While homology was found to exist throughout the two mol-
ecules, the C-terminal regions (amino acids 180-264 of 
TRAX) proved to be the most conserved (38% identity). 
TRAX contains a previously described bipartite nuclear tar-
geting motif [10] in its N-terminal region, comprising two 
basic amino acids, a spacer region of any 10 amino acids 
Fig. 4. Alignment of the human TRAX and Translin proteins. The 
alignment was maximized by introducing insertions marked by 
dashes. Residues conserved in the two sequences are boxed. The bi-
partite nuclear targeting motif in the N-terminal region of TRAX is 
underlined. 
and a basic cluster in which at least three out of the next 
five amino acids are basic (RKRKhdnfphnqRRegK, amino 
acids 11-27). 
Our previous studies indicated the native form of Translin 
to be present in the cytoplasm of cell lines of various lineages, 
while nuclear localization was limited to lymphoid lineage 
cells with rearranged Ig and TCR loci. These observations 
raise the intriguing possibility that nuclear transport of Trans-
lin is regulated in a physiologically significant way. Translin, 
however, does not contain any nuclear targeting sequences. 
Therefore, it is conceivable that other factors such as 
TRAX with nuclear targeting motifs are involved in the active 
nuclear transport of Translin. The TRAX has a heptad repeat 
of hydrophobic amino acids, leucine, alanine, leucine, leucine, 
isoleucine and leucine (amino acids 73, 80, 87, 94, 101 and 108 
respectively), which is consistent with the hypothetical struc-
ture referred to as the 'leucine zipper'. The question now has 
to be addressed whether TRAX homodimerizes or heterodi-
merizes with Translin by this putative leucine zipper motif, for 
regulating cellular functions, reminiscent of observations with 
Bcl-2-Bax [11] or Myc-Max interactions [12-15]. 
Northern blot analysis of TRAX gene expression revealed a 
single transcript of approximately 2.7 kb and the distribution 
of TRAX mRNA in various tissues was like that of Translin 
(data not shown). All of these results, including the extensive 
amino acid homology and the similar transcription pattern of 
mRNA, together with the evidence of in vivo and in vitro 
interaction of the two proteins, suggest that TRAX is a mem-
ber of the Translin protein family. 
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